Cell Sheet-based Gene Therapy Market Expected to Surpass USD 2400 Million by 2034 Driven by Breakthroughs in Regenerative Medicine

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Cell Sheet-based Gene Therapy Market Size, Share & Trends Analysis Report By Cell-Sheet Type (Monolayer Cell-sheet Type, Co-culture Cell-sheet Type, Multilayered Cell-sheet Type, and Others), Source Type (Allogenic, Autologous, and Stem-cell Derived), Technology (Cell sheet-based Engineering Techniques [Scaffold-Free Techniques, Light-induced cell sheet technology, Layer-by-Layer Assembly, Temperature-Responsive Culture Surfaces, Others] and Gene Delivery Methods [CRISPR/Cas9, Viral Vector-Based (e.g., Lentivirus, Adenovirus), Non-Viral Vector-Based (e.g., Liposomes, Nanoparticles), Others]), Application (Oncology, Cardiology, Genetic Disorders, Ophthalmology, and Others), End-user (Hospitals and Clinics, Biotech and Pharma Companies, Research and Academic Institutions, Others),-Market Outlook And Industry Analysis 2034"

The Global Cell Sheet-based Gene Therapy Market is valued at US$ 719.9 Mn in 2024 and it is expected to reach US$ 2,405.4 Bn by the year 2034, with a CAGR of 13.1% during the forecast period of 2025-2034.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/3143

Cell sheet-based gene therapy is a state-of-the-art biomedical technique that combines gene therapy and regenerative medicine to replace or repair damaged tissues and organs. This technique includes growing genetically modified cell sheets on particular surfaces while maintaining the cells' native structure, extracellular matrix, and cell-to-cell connections. Following that, these sheets are directly transplanted onto the target tissue without the need for scaffolds or sutures. The growing prevalence of degenerative, chronic, and uncommon diseases that are difficult to treat with conventional methods is driving the global cell sheet-based gene therapy market's growth.

In addition, the growth of the cell sheet-based gene therapy market is driven by international frameworks that have enhanced the clinical and regulatory trajectory of these medications, including Japan's conditional approval approach, the FDA's RMAT designation, and the EMA's ATMP pathway. Furthermore, the industry is witnessing technical convergence due to developments in temperature-responsive polymers, gene editing integration, and cryopreservation techniques, which enable more dependable and scalable product delivery. Despite this pace, challenges persist, including unclear reimbursement, high manufacturing costs, and fragmented late-stage clinical data, which will limit the growth of the cell sheet-based gene therapy market.

List of Prominent Players in the Cell Sheet-based Gene Therapy Market:
• Abeona Therapeutics Inc.
• Emmaus Medical, Inc
• CellSeed Inc.
• Fujifilm Cellular Dynamics, Inc. (FCDI) (FUJIFILM Holdings Corporation)
• Japan Tissue Engineering Co., Ltd.
• Foundation ENEA Tech Biomedical

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-04

Market Dynamics:
Drivers-
The development of regenerative medicine technologies is one of the primary factors propelling the cell sheet-based gene therapy market. Stem cells and other cell types are used in cell sheet-based gene therapy to repair damaged or degenerated tissues. The viability and efficacy of cell-sheet therapies are becoming increasingly apparent as our knowledge of stem cell biology and tissue engineering advances. These technologies make it possible to heal tissues, including corneal tissue in the eye, heart muscle following a heart attack, and cartilage in joints that are not able to regenerate on their own.

Challenges:
The cell sheet-based gene therapy market expansion is being constrained by growing worries about ethical issues and regulatory approval. Gene therapies are closely regulated by agencies like the FDA and EMA, especially when they use sophisticated technologies like cell-sheet engineering. Regulating these treatments is still in its infancy, and the approval process can be drawn out, costly, and unpredictable. In addition to increasing the overall cost of development, the drawn-out and expensive regulatory approval process delays the availability of these therapies to patients. Additionally, since cell-sheet-based gene therapies are still in their infancy, it isn't easy to set precise standards for them.

Regional Trends:
The region's sophisticated healthcare system, high concentration of biotechnology and gene therapy firms, and significant investment in regenerative medicine research are all contributing to North America's notable growth in the cell sheet-based gene therapy market. The existence of major firms, advantageous regulatory frameworks, and growing clinical studies centred on cell sheet engineering for illnesses relating to the heart, eyes, and skin have made the United States the industry leader. Additionally, early adoption of cutting-edge cell-based medicines and increasing public and private funding are driving additional growth.

However, the Asia-Pacific market for cell sheet-based gene therapy is anticipated to rise significantly due to Japan's progressive regulatory framework, growing clinical activity, and robust academic-industry cooperation. The PMDA's fast-track approval pathways and Japan's Act on the Safety of Regenerative Medicine are two examples of advanced regenerative medicine frameworks that benefit the region. These frameworks have expedited the development and approval of treatments such as JACC and Holoclar.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/3143

Recent Developments:
• May 2025: The autologous cultured cartilage product JACC, developed by Japan Tissue Engineering Co., Ltd. (J-TEC), has been approved by the regulatory body to treat osteoarthritis in the knee, expanding its orthopaedic uses beyond its original indications.
• December 2024: J-TEC and VCCT Inc. formed a business and financial partnership to work together on the development of cell sheet engineering-based retinal regeneration treatments obtained from iPS cells. By assisting with preclinical research and pipeline expansion, VCCT will strengthen both businesses' standing in the ocular regenerative sector.

Segmentation of Cell Sheet-based Gene Therapy Market-
By Cell-Sheet Type-
• Monolayer Cell-sheet Type
• Co-culture Cell-sheet Type
• Multilayered Cell-sheet Type
• Others
By Source Type -
• Allogenic
• Autologous
• Stem-cell Derived
By Technology-
• Cell sheet-based Engineering Techniques
o Scaffold-Free Techniques
o Light-induced cell sheet technology
o Layer-by-Layer Assembly
o Temperature-Responsive Culture Surfaces
o Others
• Gene Delivery Methods
o CRISPR/Cas9
o Viral Vector-Based (e.g., Lentivirus, Adenovirus)
o Non-Viral Vector-Based (e.g., Liposomes, Nanoparticles)
o Others
By Application-
• Oncology
• Cardiology
• Genetic Disorders
• Ophthalmology
• Others
By End-user-
• Hospitals and Clinics
• Biotech and Pharma Companies
• Research and Academic Institutions
• Others
By Region-
North America-
• The US
• Canada
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Mexico
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/cell-sheet-based-gene-therapy-market/3143

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.